Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec;35(12):3448.
doi: 10.1038/s41433-020-01327-7. Epub 2021 Jun 4.

Reply to: 'Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy'

Andrew Lotery  1 , Sobha Sivaprasad  2 , Abby O'Connell  3 , Barnaby Reeves  3
Affiliations
Comment

Reply to: 'Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy'

Andrew Lotery et al. Eye (Lond). 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Comment on

References

    1. Xia Y & Hua R. Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy. Eye. 2020. 10.1038/s41433-020-01325-9. - PMC - PubMed
    1. Fraenkel D, Suffo S, Langenbucher A, Seitz B, Abdin AD. Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2020. 10.1177/1120672120952648. - PubMed
    1. Petkovsek DS, Cherfan DG, Conti FF, Hom GL, Ehlers JP, Babiuch AS, et al. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Br J Ophthalmol. 2020;104:182–7. doi: 10.1136/bjophthalmol-2019-314047. - DOI - PubMed
    1. Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:294–303. doi: 10.1016/S0140-6736(19)32981-2. - DOI - PubMed

MeSH terms